News coverage about Merrimack Pharmaceuticals (NASDAQ:MACK) has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Merrimack Pharmaceuticals earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 49.0766831377025 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Merrimack Pharmaceuticals (NASDAQ:MACK) traded up $0.23 during mid-day trading on Wednesday, reaching $10.28. 128,000 shares of the company traded hands, compared to its average volume of 138,945. Merrimack Pharmaceuticals has a 52 week low of $9.68 and a 52 week high of $39.90. The company has a current ratio of 3.35, a quick ratio of 3.35 and a debt-to-equity ratio of 0.45.
ILLEGAL ACTIVITY WARNING: “Merrimack Pharmaceuticals (MACK) Getting Somewhat Positive News Coverage, Report Shows” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/14/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-merrimack-pharmaceuticals-mack-stock-price.html.
About Merrimack Pharmaceuticals
Merrimack Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development.
Receive News & Ratings for Merrimack Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.